1.95
+0.07(+3.72%)
Currency In USD
| Previous Close | 1.88 |
| Open | 1.91 |
| Day High | 1.95 |
| Day Low | 1.87 |
| 52-Week High | 7.68 |
| 52-Week Low | 1 |
| Volume | 167,112 |
| Average Volume | 2.03M |
| Market Cap | 60.55M |
| PE | -0.99 |
| EPS | -1.97 |
| Moving Average 50 Days | 2.06 |
| Moving Average 200 Days | 1.73 |
| Change | 0.07 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $110.86 as of February 05, 2025 at a share price of $1.95. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $195 as of February 05, 2025 at a share price of $1.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 03, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced th
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Ne
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
GlobeNewswire Inc.
Jan 07, 2025 12:00 PM GMT
- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial und